newsfilter
← Latest News
Business Wire·

Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment

Data to be discussed in a Spotlight Poster Presentation at the 2022 San Antonio Breast Cancer Symposium Preliminary Phase 2 results from ACE-Breast-03 study demonstrate 57.1% confirmed overall response rate (ORR) by